MarketPulse
I

$IRON

3 articles found
0 positive
2 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Disc Medicine Stock Collapses on FDA Rejection; Law Firm Probes Securities Fraud

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.
IRONsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Disc Medicine Stock Plunges 22% After FDA Rejects Bitopertin Drug Application

FDA rejects Disc Medicine's bitopertin drug, triggering 22% stock decline and securities investigation into potential investor losses.
IRONsecurities fraudclass action lawsuit
The Motley FoolThe Motley Fool··Jonathan Ponciano

BVF's $52M Stake in Disc Medicine Signals Confidence Despite Regulatory Hurdles

BVF Partners invests $52M in Disc Medicine despite FDA setbacks, betting on Phase 3 trial data and strong cash reserves through 2029.
KYMRRVMDRVMDWIRONFDA approvalclinical trial